ESTRELLA IMMUNOPHARMA, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $14.47 thousand for the 9-month period ending 2023-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-05-15
- ESTRELLA IMMUNOPHARMA, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-03-31 was $5.49K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2023-03-31 | $5.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $14.47K 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $8.98K 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |